And so it goes -- this time, it was in patients with advanced or recurrent endometrial carcinoma -- in a combo with Esai's latest.
Keytruda is and will remain the world's highest revenue drug franchise.
Onward, grinning -- into a sunny Friday morning. . . .
नमस्ते
No comments:
Post a Comment